Avidity Partners Management’s Editas Medicine EDIT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q4
Sell
-1,465,000
Closed -$5M 70
2024
Q3
$5M Buy
1,465,000
+649,000
+80% +$2.83M 0.25% 67
2024
Q2
$3.81M Buy
+816,000
New +$4.6M 0.16% 74
2023
Q3
Sell
-3,000,000
Closed -$24.7M 92
2023
Q2
$24.7M Buy
+3,000,000
New +$26.1M 0.86% 47
2020
Q3
Sell
-600,000
Closed -$17.7M 75
2020
Q2
$17.7M Buy
+600,000
New +$15.7M 1.14% 35

Other funds holding EDIT

Avidity Partners Management's EDIT Position: Q4 2024 in Review

Avidity Partners Management sold out of Editas Medicine (EDIT) in Q4 2024, closing a stake of 1,465,000 shares — an estimated $5M sold.

Avidity Partners Management first reported a position in EDIT in Q2 2020 and held it in 4 quarters. The position peaked at $24.7M in Q2 2023. 206 funds tracked by Wall St. Rank hold EDIT as of Q4 2024.

  • Avidity Partners Management reported no remaining Editas Medicine position as of Q4 2024 after selling out during the quarter.
  • Avidity Partners Management sold 1,465,000 Editas Medicine shares in Q4 2024, an estimated $5M.
  • Avidity Partners Management first reported a position in Editas Medicine in Q2 2020 and held it in 4 quarters.
  • Avidity Partners Management's Editas Medicine position peaked at $24.7M in Q2 2023.
  • 206 funds tracked by Wall St. Rank held Editas Medicine as of Q4 2024.

Based on Avidity Partners Management's 13F filing for Q4 2024, filed 14 Feb 2025.